Total Payments
$28,373
2024 Payments
$3,005
Companies
45
Transactions
1,537
Medicare Patients
32,739
Medicare Billing
$14.2M
Payment Breakdown by Category
Food & Beverage$25,152 (88.6%)
Other$2,700 (9.5%)
Consulting$300.00 (1.1%)
Education$220.82 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $25,152 | 1,530 | 88.6% |
| Honoraria | $2,700 | 2 | 9.5% |
| Consulting Fee | $300.00 | 1 | 1.1% |
| Education | $220.82 | 4 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $4,857 | 240 | $0 (2024) |
| Amgen Inc. | $4,395 | 252 | $0 (2024) |
| PFIZER INC. | $3,217 | 232 | $0 (2024) |
| UCB, Inc. | $2,126 | 87 | $0 (2024) |
| Horizon Pharma plc | $2,092 | 32 | $0 (2018) |
| Horizon Therapeutics plc | $1,600 | 30 | $0 (2023) |
| Janssen Biotech, Inc. | $1,335 | 93 | $0 (2024) |
| Lilly USA, LLC | $1,325 | 133 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,106 | 66 | $0 (2024) |
| Genentech USA, Inc. | $1,083 | 83 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,005 | 144 | ABBVIE INC. ($792.78) |
| 2023 | $3,408 | 164 | AbbVie Inc. ($723.54) |
| 2022 | $3,193 | 153 | ABBVIE INC. ($992.95) |
| 2021 | $2,499 | 139 | AbbVie Inc. ($713.15) |
| 2020 | $3,379 | 134 | Horizon Therapeutics plc ($1,243) |
| 2019 | $3,971 | 272 | Amgen Inc. ($593.21) |
| 2018 | $4,138 | 290 | PFIZER INC. ($957.48) |
| 2017 | $4,779 | 241 | Horizon Pharma plc ($1,909) |
All Payment Transactions
1,537 individual payment records from CMS Open Payments — Page 1 of 62
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $1.07 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Inflammation | ||||||
| 12/09/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $36.61 | General |
| Category: Rheumatology | ||||||
| 12/09/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: Bone Health | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $7.28 | General |
| Category: Inflammation | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.93 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Dermatology | ||||||
| 11/26/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/25/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $39.07 | General |
| Category: Immunology | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Sandoz Inc. | TREPROSTINIL (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 11/20/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Inflammation | ||||||
| 11/19/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: Inflammation | ||||||
| 11/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $13.48 | General |
| 11/04/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $18.62 | General |
| 10/28/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/25/2024 | Fresenius Kabi USA, LLC | Tyenne (Biological) | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: Biosimilars | ||||||
| 10/24/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $31.32 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $29.18 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/14/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $43.39 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 58 | 7,944 | 321,489 | $9.5M | $3.5M |
| 2022 | 64 | 8,681 | 336,803 | $9.6M | $3.6M |
| 2021 | 66 | 8,350 | 329,230 | $8.9M | $3.6M |
| 2020 | 67 | 7,764 | 277,201 | $8.6M | $3.5M |
Total Patients
32,739
Total Services
1,264,723
Medicare Billing
$14.2M
Procedure Codes
255
All Medicare Procedures & Services
255 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 389 | 36,780 | $1.5M | $679,677 | 44.0% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 87 | 56,652 | $2.8M | $595,196 | 21.0% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 33 | 15,550 | $1.1M | $524,838 | 46.2% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 58 | 52,290 | $522,900 | $407,280 | 77.9% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 27 | 79,503 | $548,919 | $365,687 | 66.6% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 11 | 2,580 | $340,560 | $163,753 | 48.1% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 14 | 40,400 | $484,800 | $157,998 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 620 | 1,117 | $227,868 | $99,914 | 43.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 206 | 919 | $312,460 | $90,057 | 28.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 22 | 2,600 | $335,400 | $68,709 | 20.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 313 | 478 | $138,620 | $63,983 | 46.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 433 | 1,054 | $125,426 | $55,837 | 44.5% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2023 | 15 | 1,870 | $220,800 | $55,703 | 25.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 210 | 210 | $86,730 | $32,867 | 37.9% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 88 | 313 | $56,880 | $19,909 | 35.0% |
| 82306 | Vitamin d-3 level | Office | 2023 | 367 | 575 | $132,250 | $16,681 | 12.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 707 | 1,596 | $35,112 | $16,488 | 47.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 718 | 1,679 | $20,148 | $14,092 | 69.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 504 | 1,237 | $43,295 | $9,397 | 21.7% |
| J7328 | Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | Office | 2023 | 20 | 17,309 | $51,927 | $8,867 | 17.1% |
| 86480 | Tuberculosis test, gamma interferon | Office | 2023 | 121 | 122 | $19,520 | $7,410 | 38.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 61 | 314 | $37,680 | $6,777 | 18.0% |
| 77085 | Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | Office | 2023 | 118 | 118 | $13,216 | $5,987 | 45.3% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 461 | 1,159 | $20,862 | $5,873 | 28.2% |
| 73120 | X-ray of hand, 2 views | Office | 2023 | 154 | 311 | $17,160 | $4,729 | 27.6% |
About Dr. Saima Chohan, MD
Dr. Saima Chohan, MD is a Rheumatology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073675526.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Saima Chohan, MD has received a total of $28,373 in payments from pharmaceutical and medical device companies, with $3,005 received in 2024. These payments were reported across 1,537 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($25,152).
As a Medicare-enrolled provider, Chohan has provided services to 32,739 Medicare beneficiaries, totaling 1,264,723 services with total Medicare billing of $14.2M. Data is available for 4 years (2020–2023), covering 255 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Phoenix, AZ
- Active Since 12/14/2006
- Last Updated 08/23/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1073675526
Products in Payments
- XELJANZ (Drug) $2,826
- Enbrel (Biological) $2,796
- RINVOQ (Biological) $2,571
- Cimzia (Drug) $1,973
- KRYSTEXXA (Drug) $1,875
- KRYSTEXXA (Biological) $1,612
- TALTZ (Drug) $1,035
- Humira (Biological) $1,033
- ORENCIA (Biological) $825.63
- EVENITY (Biological) $823.07
- TREMFYA (Drug) $740.40
- COSENTYX (Biological) $718.17
- Rituxan (Biological) $634.29
- BENLYSTA (Biological) $606.15
- ACTHAR (Biological) $600.33
- Actemra (Biological) $427.85
- KEVZARA (Drug) $418.24
- SKYRIZI (Biological) $413.04
- Prolia (Biological) $381.28
- FORTEO (Drug) $290.79
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Phoenix
John Tesser, Md, MD
Rheumatology — Payments: $1.6M
Rheumatology $1.6M
Dr. Nehad Soloman, M.d, M.D
Rheumatology — Payments: $1.6M
Rheumatology $1.6M
Dr. Kelly Krohn, M.d, M.D
Rheumatology — Payments: $344,000
Rheumatology $344,000
Paul Caldron, Do, DO
Rheumatology — Payments: $51,633
Rheumatology $51,633
Nikila Kumar, M.d, M.D
Rheumatology — Payments: $16,559
Rheumatology $16,559
Dr. Trent Smith, M.d, M.D
Rheumatology — Payments: $16,166
Rheumatology $16,166